Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to dete...
| Autores: | , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Servizo Galego de Saúde (SERGAS) |
| Repositorio: | RUNA. Repositorio da Consellería de Sanidade e Sergas |
| OAI Identifier: | oai:runa.sergas.gal:20.500.11940/16019 |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pubmed/30718554 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361883/pdf/41598_2018_Article_37328.pdf http://hdl.handle.net/20.500.11940/16019 |
| Access Level: | acceso abierto |
| Palabra clave: | Middle Aged Cross-Sectional Studies RNA Coinfection Immunoglobulin G Prevalence Hepatitis Antibodies Hepatitis C Humans HIV-1 HIV Infections Hepatitis E virus Hepatitis E ARN VIH-1 inmunoglobulina G virus de la hepatitis E prevalencia hepatitis E hepatitis C mediana edad humanos coinfección estudios transversales anticuerpos de las hepatitis infecciones por VIH CHUVI |
| Sumario: | Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm(3) had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells >/= 350 cells/mm(3) (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm(3). |
|---|